Analyst Price Targets — BWAY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 26, 2026 11:07 am | — | H.C. Wainwright | $30.00 | $23.04 | TheFly | Brainsway price target raised to $30 from $24 at H.C. Wainwright |
| January 22, 2026 2:01 pm | — | Northland Securities | $30.00 | $24.61 | TheFly | Brainsway price target raised to $30 from $23 at Northland |
| December 8, 2025 11:15 am | Raghuram Selvaraju | H.C. Wainwright | $24.00 | $17.27 | TheFly | Brainsway price target raised to $24 from $18 at H.C. Wainwright |
| August 7, 2024 6:14 am | Raghuram Selvaraju | H.C. Wainwright | $16.00 | $6.89 | TheFly | Brainsway price target raised to $16 from $15 at H.C. Wainwright |
| May 9, 2024 7:36 am | Steven Lichtman | Oppenheimer | $11.00 | $5.70 | StreetInsider | Brainsway (BWAY) PT Raised to $11 at Oppenheimer |
| May 9, 2024 6:42 am | Raghuram Selvaraju | H.C. Wainwright | $15.00 | $5.70 | StreetInsider | Brainsway (BWAY) PT Raised to $15 at H.C. Wainwright |
| November 17, 2022 9:50 am | — | Northland Securities | $5.00 | $1.98 | Benzinga | Northland Capital Markets Maintains Outperform on BrainsWay, Lowers Price Target to $5 |
| August 22, 2022 6:21 am | — | H.C. Wainwright | $16.00 | $4.92 | Benzinga | HC Wainwright & Co. Maintains Buy on BrainsWay, Raises Price Target to $16 |
| August 11, 2022 7:35 am | — | Raymond James | $8.00 | $5.67 | Benzinga | Raymond James Maintains Outperform on BrainsWay, Lowers Price Target to $8 |
Latest News for BWAY
BURLINGTON, Mass. and JERUSALEM, Feb. 25, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation technologies, today announced that it will report its fourth quarter and full year 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, March 11, 2026. The…
BrainsWay continues to activel y evaluat e similar investments in l eading North American m ental h ealth p roviders to raise awareness and e xpand a ccess to transformative care
BURLINGTON, Mass. and JERUSALEM, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today commented on the recent news issued by Evernorth® Behavioral Health, Inc., a division of the Cigna Group, which serves over 18 million covered lives across 12 states, that it will no longer require prior…
Change in ADS ratio aimed at simplifying comparisons to ordinary shares traded on the Tel Aviv Stock Exchange, while boosting liquidity and access for U.S. investors Change in ADS ratio aimed at simplifying comparisons to ordinary shares traded on the Tel Aviv Stock Exchange, while boosting liquidity and access for U.S. investors
Brainsway (NASDAQ: BWAY - Get Free Report) and MariMed (OTCMKTS:MRMD - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends. Risk and Volatility Brainsway has a beta of 1.2,
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for BWAY.
Senate Trading
No Senate trades found for BWAY.
U.S. House Trading
No House trades found for BWAY.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.